TD Cowen 44th Annual Healthcare
Conference on March 5 in Boston
Leerink Partners Global Biopharma
Conference on March 12 in
Miami
Barclays 26th Annual Global
Healthcare Conference on March 13 in
Miami
SAN
DIEGO, Feb. 27, 2024 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) will participate at three upcoming
investor conferences in March.
- Matt Abernethy, Chief Financial
Officer, and Kyle Gano, Chief
Business Development and Strategy Officer, will present at the TD
Cowen 44th Annual Healthcare Conference at 11:10 a.m. Eastern Time on Tuesday March 5, 2024
in Boston.
- Matt Abernethy and Kyle Gano will present at the Leerink Partners
Global Biopharma Conference at 8:40 a.m.
Eastern Time on Tuesday March 12, 2024 in Miami.
- Kyle Gano and Todd Tushla, Vice President of Investor
Relations, will present at the Barclays 26th Annual
Global Healthcare Conference at 10:15 a.m.
Eastern Time on Wednesday March 13, 2024 in Miami.
The live presentations will be webcast and may be accessed on
Neurocrine Biosciences' website under Investors at
www.neurocrine.com. A replay of the webcast will be available on
the website approximately one hour after the conclusion of the
event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is
a leading neuroscience-focused, biopharmaceutical company with a
simple purpose: to relieve suffering for people with great needs,
but few options. We are dedicated to discovering and developing
life-changing treatments for patients with under-addressed
neurological, neuroendocrine, and neuropsychiatric disorders. The
company's diverse portfolio includes FDA-approved treatments for
tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and
uterine fibroids*, as well as a robust pipeline including multiple
compounds in mid- to late-phase clinical development across our
core therapeutic areas. For three decades, we have applied our
unique insight into neuroscience and the interconnections between
brain and body systems to treat complex conditions. We relentlessly
pursue medicines to ease the burden of debilitating diseases and
disorders, because you deserve brave science. For more information,
visit neurocrine.com, and follow the company on LinkedIn, X
(Formerly Twitter) and Facebook. (*in collaboration with
AbbVie)
NEUROCRINE is a registered trademark of Neurocrine Biosciences,
Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences,
Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-investor-conferences-in-march-302073239.html
SOURCE Neurocrine Biosciences, Inc.